APO Research
Talk to an analyst

APO RESEARCH · REPORT

NFkB p65 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global NFkB p65 Antibody Market Outlook and Growth Opportunities 2026

19 December 2025191 pages

Choose your research edition.

Industry ResearchNFkB p65 Antibody Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal NFkB p65 Antibody Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal NFkB p65 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NFkB p65 Antibody Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal NFkB p65 Antibody Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global NFkB p65 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for NFkB p65 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for NFkB p65 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for NFkB p65 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the NFkB p65 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the NFkB p65 Antibody market include Thermo Fisher Scientific, Merck, United States Biological, Santa Cruz Biotechnology, Proteintech, LSBio, GeneTex, FineTest and Cell Signaling Technology, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global NFkB p65 Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of NFkB p65 Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents NFkB p65 Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global NFkB p65 Antibody market.

NFkB p65 Antibody Segment by Company

Thermo Fisher Scientific

Merck

United States Biological

Santa Cruz Biotechnology

Proteintech

LSBio

GeneTex

FineTest

Cell Signaling Technology

Boster Biological Technology

Bio-Rad

Aviva Systems Biology

NFkB p65 Antibody Segment by Type

Monoclonal

Polyclonal

NFkB p65 Antibody Segment by Application

Western Blot

Immunoprecipitation

Immunocytochemistry

Immunofluorescence

Others

NFkB p65 Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global NFkB p65 Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the NFkB p65 Antibody key companies, revenue, market share, and recent developments.

3. To split the NFkB p65 Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions NFkB p65 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify NFkB p65 Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze NFkB p65 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NFkB p65 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NFkB p65 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NFkB p65 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global NFkB p65 Antibody industry.

Chapter 3: Detailed analysis of NFkB p65 Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of NFkB p65 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of NFkB p65 Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. NFkB p65 Antibody Industry Trends Table 2. NFkB p65 Antibody Industry Drivers Table 3. NFkB p65 Antibody Industry Opportunities and Challenges Table 4. NFkB p65 Antibody Industry Restraints Table 5. Global NFkB p65 Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global NFkB p65 Antibody Revenue Share by Company (2021-2026) Table 7. Global NFkB p65 Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global NFkB p65 Antibody Key Company Manufacturing Base & Headquarters Table 9. Global NFkB p65 Antibody Company, Product Type & Application Table 10. Global NFkB p65 Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global NFkB p65 Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Monoclonal Table 15. Significant Companies of Polyclonal Table 16. Global NFkB p65 Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global NFkB p65 Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global NFkB p65 Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global NFkB p65 Antibody Sales Value Share by Type (2021-2026) Table 20. Global NFkB p65 Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Western Blot Table 22. Significant Companies of Immunoprecipitation Table 23. Significant Companies of Immunocytochemistry Table 24. Significant Companies of Immunofluorescence Table 25. Significant Companies of Others Table 26. Global NFkB p65 Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global NFkB p65 Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global NFkB p65 Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global NFkB p65 Antibody Sales Value Share by Application (2021-2026) Table 30. Global NFkB p65 Antibody Sales Value Share by Application (2027-2032) Table 31. Global NFkB p65 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global NFkB p65 Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global NFkB p65 Antibody Sales Value Share by Region (2021-2026) Table 34. Global NFkB p65 Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global NFkB p65 Antibody Sales Value Share by Region (2027-2032) Table 36. Global NFkB p65 Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global NFkB p65 Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global NFkB p65 Antibody Sales Value Market Share by Country (2021-2026) Table 39. Global NFkB p65 Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global NFkB p65 Antibody Sales Value Market Share by Country (2027-2032) Table 41. Thermo Fisher Scientific Company Information Table 42. Thermo Fisher Scientific Business Overview Table 43. Thermo Fisher Scientific NFkB p65 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Thermo Fisher Scientific NFkB p65 Antibody Product Portfolio Table 45. Thermo Fisher Scientific Recent Development Table 46. Merck Company Information Table 47. Merck Business Overview Table 48. Merck NFkB p65 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Merck NFkB p65 Antibody Product Portfolio Table 50. Merck Recent Development Table 51. United States Biological Company Information Table 52. United States Biological Business Overview Table 53. United States Biological NFkB p65 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. United States Biological NFkB p65 Antibody Product Portfolio Table 55. United States Biological Recent Development Table 56. Santa Cruz Biotechnology Company Information Table 57. Santa Cruz Biotechnology Business Overview Table 58. Santa Cruz Biotechnology NFkB p65 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Santa Cruz Biotechnology NFkB p65 Antibody Product Portfolio Table 60. Santa Cruz Biotechnology Recent Development Table 61. Proteintech Company Information Table 62. Proteintech Business Overview Table 63. Proteintech NFkB p65 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Proteintech NFkB p65 Antibody Product Portfolio Table 65. Proteintech Recent Development Table 66. LSBio Company Information Table 67. LSBio Business Overview Table 68. LSBio NFkB p65 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. LSBio NFkB p65 Antibody Product Portfolio Table 70. LSBio Recent Development Table 71. GeneTex Company Information Table 72. GeneTex Business Overview Table 73. GeneTex NFkB p65 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. GeneTex NFkB p65 Antibody Product Portfolio Table 75. GeneTex Recent Development Table 76. FineTest Company Information Table 77. FineTest Business Overview Table 78. FineTest NFkB p65 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. FineTest NFkB p65 Antibody Product Portfolio Table 80. FineTest Recent Development Table 81. Cell Signaling Technology Company Information Table 82. Cell Signaling Technology Business Overview Table 83. Cell Signaling Technology NFkB p65 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Cell Signaling Technology NFkB p65 Antibody Product Portfolio Table 85. Cell Signaling Technology Recent Development Table 86. Boster Biological Technology Company Information Table 87. Boster Biological Technology Business Overview Table 88. Boster Biological Technology NFkB p65 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Boster Biological Technology NFkB p65 Antibody Product Portfolio Table 90. Boster Biological Technology Recent Development Table 91. Bio-Rad Company Information Table 92. Bio-Rad Business Overview Table 93. Bio-Rad NFkB p65 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Bio-Rad NFkB p65 Antibody Product Portfolio Table 95. Bio-Rad Recent Development Table 96. Aviva Systems Biology Company Information Table 97. Aviva Systems Biology Business Overview Table 98. Aviva Systems Biology NFkB p65 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Aviva Systems Biology NFkB p65 Antibody Product Portfolio Table 100. Aviva Systems Biology Recent Development Table 101. Research Programs/Design for This Report Table 102. Authors List of This Report Table 103. Secondary Sources Table 104. Primary Sources List of Figures Figure 1. NFkB p65 Antibody Product Image Figure 2. Global NFkB p65 Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NFkB p65 Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global NFkB p65 Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Monoclonal Image Figure 8. Polyclonal Image Figure 9. Global NFkB p65 Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global NFkB p65 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global NFkB p65 Antibody Sales Value Share by Type (2021-2032) Figure 12. Western Blot Image Figure 13. Immunoprecipitation Image Figure 14. Immunocytochemistry Image Figure 15. Immunofluorescence Image Figure 16. Others Image Figure 17. Global NFkB p65 Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global NFkB p65 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global NFkB p65 Antibody Sales Value Share by Application (2021-2032) Figure 20. Global NFkB p65 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global NFkB p65 Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America NFkB p65 Antibody Sales Value (2021-2032) & (US$ Million) Figure 23. North America NFkB p65 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe NFkB p65 Antibody Sales Value (2021-2032) & (US$ Million) Figure 25. Europe NFkB p65 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific NFkB p65 Antibody Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific NFkB p65 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America NFkB p65 Antibody Sales Value (2021-2032) & (US$ Million) Figure 29. South America NFkB p65 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa NFkB p65 Antibody Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa NFkB p65 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt NFkB p65 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal
  • Polyclonal
Applications
  • Western Blot
  • Immunoprecipitation
  • Immunocytochemistry
  • Immunofluorescence
  • Others
Companies covered
  • Thermo Fisher Scientific
  • Merck
  • United States Biological
  • Santa Cruz Biotechnology
  • Proteintech
  • LSBio
  • GeneTex
  • FineTest
  • Cell Signaling Technology
  • Boster Biological Technology
  • Bio-Rad
  • Aviva Systems Biology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global NFkB p65 Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global NFkB p65 Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 NFkB p65 Antibody Market Dynamics
  1. 2.1 NFkB p65 Antibody Industry Trends
  2. 2.2 NFkB p65 Antibody Industry Drivers
  3. 2.3 NFkB p65 Antibody Industry Opportunities and Challenges
  4. 2.4 NFkB p65 Antibody Industry Restraints
3 NFkB p65 Antibody Market by Company
  1. 3.1 Global NFkB p65 Antibody Company Revenue Ranking in 2025
  2. 3.2 Global NFkB p65 Antibody Revenue by Company (2021-2026)
  3. 3.3 Global NFkB p65 Antibody Company Ranking (2024-2026)
  4. 3.4 Global NFkB p65 Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global NFkB p65 Antibody Company Product Type and Application
  6. 3.6 Global NFkB p65 Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global NFkB p65 Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 NFkB p65 Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 NFkB p65 Antibody Market by Type
  1. 4.1 NFkB p65 Antibody Type Introduction
  2. 4.1.1 Monoclonal
  3. 4.1.2 Polyclonal
  4. 4.2 Global NFkB p65 Antibody Sales Value by Type
  5. 4.2.1 Global NFkB p65 Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global NFkB p65 Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global NFkB p65 Antibody Sales Value Share by Type (2021-2032)
5 NFkB p65 Antibody Market by Application
  1. 5.1 NFkB p65 Antibody Application Introduction
  2. 5.1.1 Western Blot
  3. 5.1.2 Immunoprecipitation
  4. 5.1.3 Immunocytochemistry
  5. 5.1.4 Immunofluorescence
  6. 5.1.5 Others
  7. 5.2 Global NFkB p65 Antibody Sales Value by Application
  8. 5.2.1 Global NFkB p65 Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global NFkB p65 Antibody Sales Value by Application (2021-2032)
  10. 5.2.3 Global NFkB p65 Antibody Sales Value Share by Application (2021-2032)
6 NFkB p65 Antibody Regional Value Analysis
  1. 6.1 Global NFkB p65 Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global NFkB p65 Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global NFkB p65 Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global NFkB p65 Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America NFkB p65 Antibody Sales Value (2021-2032)
  7. 6.3.2 North America NFkB p65 Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe NFkB p65 Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe NFkB p65 Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific NFkB p65 Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific NFkB p65 Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America NFkB p65 Antibody Sales Value (2021-2032)
  16. 6.6.2 South America NFkB p65 Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa NFkB p65 Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa NFkB p65 Antibody Sales Value Share by Country, 2025 VS 2032
7 NFkB p65 Antibody Country-level Value Analysis
  1. 7.1 Global NFkB p65 Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global NFkB p65 Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global NFkB p65 Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global NFkB p65 Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt NFkB p65 Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt NFkB p65 Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt NFkB p65 Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific NFkB p65 Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific NFkB p65 Antibody Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck NFkB p65 Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck NFkB p65 Antibody Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 United States Biological
  14. 8.3.1 United States Biological Company Information
  15. 8.3.2 United States Biological Business Overview
  16. 8.3.3 United States Biological NFkB p65 Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 United States Biological NFkB p65 Antibody Product Portfolio
  18. 8.3.5 United States Biological Recent Developments
  19. 8.4 Santa Cruz Biotechnology
  20. 8.4.1 Santa Cruz Biotechnology Company Information
  21. 8.4.2 Santa Cruz Biotechnology Business Overview
  22. 8.4.3 Santa Cruz Biotechnology NFkB p65 Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Santa Cruz Biotechnology NFkB p65 Antibody Product Portfolio
  24. 8.4.5 Santa Cruz Biotechnology Recent Developments
  25. 8.5 Proteintech
  26. 8.5.1 Proteintech Company Information
  27. 8.5.2 Proteintech Business Overview
  28. 8.5.3 Proteintech NFkB p65 Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Proteintech NFkB p65 Antibody Product Portfolio
  30. 8.5.5 Proteintech Recent Developments
  31. 8.6 LSBio
  32. 8.6.1 LSBio Company Information
  33. 8.6.2 LSBio Business Overview
  34. 8.6.3 LSBio NFkB p65 Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 LSBio NFkB p65 Antibody Product Portfolio
  36. 8.6.5 LSBio Recent Developments
  37. 8.7 GeneTex
  38. 8.7.1 GeneTex Company Information
  39. 8.7.2 GeneTex Business Overview
  40. 8.7.3 GeneTex NFkB p65 Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GeneTex NFkB p65 Antibody Product Portfolio
  42. 8.7.5 GeneTex Recent Developments
  43. 8.8 FineTest
  44. 8.8.1 FineTest Company Information
  45. 8.8.2 FineTest Business Overview
  46. 8.8.3 FineTest NFkB p65 Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 FineTest NFkB p65 Antibody Product Portfolio
  48. 8.8.5 FineTest Recent Developments
  49. 8.9 Cell Signaling Technology
  50. 8.9.1 Cell Signaling Technology Company Information
  51. 8.9.2 Cell Signaling Technology Business Overview
  52. 8.9.3 Cell Signaling Technology NFkB p65 Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Cell Signaling Technology NFkB p65 Antibody Product Portfolio
  54. 8.9.5 Cell Signaling Technology Recent Developments
  55. 8.10 Boster Biological Technology
  56. 8.10.1 Boster Biological Technology Company Information
  57. 8.10.2 Boster Biological Technology Business Overview
  58. 8.10.3 Boster Biological Technology NFkB p65 Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Boster Biological Technology NFkB p65 Antibody Product Portfolio
  60. 8.10.5 Boster Biological Technology Recent Developments
  61. 8.11 Bio-Rad
  62. 8.11.1 Bio-Rad Company Information
  63. 8.11.2 Bio-Rad Business Overview
  64. 8.11.3 Bio-Rad NFkB p65 Antibody Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bio-Rad NFkB p65 Antibody Product Portfolio
  66. 8.11.5 Bio-Rad Recent Developments
  67. 8.12 Aviva Systems Biology
  68. 8.12.1 Aviva Systems Biology Company Information
  69. 8.12.2 Aviva Systems Biology Business Overview
  70. 8.12.3 Aviva Systems Biology NFkB p65 Antibody Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Aviva Systems Biology NFkB p65 Antibody Product Portfolio
  72. 8.12.5 Aviva Systems Biology Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst